DW-MSC for IPF / Daewoong Pharma - LARVOL DELTA

Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects (ACR Convergence 2023) - "Therefore, we evaluated whether DW-MSC can improve lung fibrosis in IPF and RA-ILD, and to identify the mechanism of improvement... DW-MSCs attenuates Bleomycin-induced and Collagen-induced pulmonary fibrosis. The therapeutic efficacy of DW-MSCs was found to be comparable to Nintedanib... Our study provides compelling evidence for the therapeutic potential of DW-MSCs in improving IPF and RA-ILD. A single administration, DW-MSCs exhibit beneficial effects on AECs injury, inflammation, and fibrosis. These effects are achieved through the protection of AECs by inhibiting apoptosis, facilitating mitochondrial transfer, and exerting immunomodulatory and anti-fibrotic effects."

Immunomodulating • IO biomarker • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • BCL2